Mar 17, 2022

Bukwang Announces Completion of SOL-804’s Phase 1 clinical trial 기사공유하기 Kim Min-jee Headquarters of Bukwang Pharmaceutical Bukwang Pharmaceutical announced the completion of SOL-804’s phase 1 clinical trial through Dyna therapeutics, a subsidiary company of Bukwang. This study is for finding the right dosage of the drug and conducted in Seoul National Univ. hospital with 40 patients. It was compared to Zytiga as a control drug in the safety, tolerance, and pharmacodynamics characteristics and was conducted in a way of randomized, crossed, and single dose administered. SOL-804 is an improved and proprietary formulated version of a currently available drug for the treatment of metastatic castration-resistant prostate cancer. It is expected to improve the convenience and drug compliance of the patients. Buwang is going to conduct a clinical trial for the permission after dose finding with this result of SOL-804’s phase 1 study. This is a strategy for the rapid permission and Bukwang will secure the advantage compared to the control drug(Zytiga) through conducting another clinical trial which finds out if it would improve the problem of taking steroids. The global market size of prostate cancer has been getting bigger and passed over 12 trillion dollars in 2019. It will reach 23 trillion dollars in 2027. The subsidiary of Bukwang, Dyna Therapeutics (“Dyna”) registered a composition patent for anti-cancer drug ‘SOL-804’ (Title: Solid oral formulation of lipophilic compound) to the U.S. The patent is also approved in Japan, Eurasia, Europe, Australia, Mexico, and Singapore, etc. Bukwang has been also improving new immuno-oncology therapeutics for global markets targeting the AhR pathway through JaguAhR Therapeutics, a joint venture between Bukwang and ASLAN Pharmaceuticals. Bukwang is also focusing on  CAR-T treatment  with another bio venture, ImmPACT Bio USA Inc. It is developing a novel set of engineered T-cell therapeutics that target loss of genes in solid tumors. Bukwang said, “They secured funding to improve anti-cancer medicine which requires great expense through joint management with OCI.” 저작권자 © Korea IT Times 무단전재 및 재배포 금지